At a glance
ClinicalIndex Comparison RecordPhase 4Unknown· 114 target
Drug / intervention
Cerebralcare pills +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CerebrAlcare Pills on CereBral Small VesseL DiseasE（CABLE）：A Randomized, Double-blinded, Placebo-controlled, Multi-center Trial
In Brief
A Phase 4 clinical trial evaluating Cerebralcare pills and Cerebralcare pills placebo for Cerebral Small Vessel Diseases. Targeting 114 participants across 1 site.
Detailed Summary
This is a randomized, double-blinded, placebo-controlled, multicenter trial. Cerebral small vessel disease (CSVD) patients will be diagnosed by Magnetic Resonance Imaging (MRI) and randomized into treatment or control groups. The purpose of this trial is to assess the efficacy of cerebralcare pills on cerebral small vessel disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCerebral Small Vessel Diseases
CountriesChina
CollaboratorsTasly Pharmaceutical Group Co., Ltd
Timeline
Phase 4UnknownOverdue
2023202420252026
Enrollment StartJun 2022
First PostedOct 2022
Primary CompletionDec 2023
Study CompletionMar 2024
TodayJul 2026
First PostedOct 13, 2022
Enrollment StartJun 5, 2022
Primary CompletionDec 31, 2023
Study CompletionMar 31, 2024
TodayJul 1, 2026
Enrollment to primary: 1.6 yearsPosted 3.7 years ago
Interventions
Cerebralcare pillsdrug
a dose of 2 packages, twice a day of Cerebralcare pills
Cerebralcare pills placebodrug
Cerebralcare pills placebo will be administrated at the same rate with experimental group